Lipella Pharmaceuticals Inc.
LIPO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 19.3% | 144.2% | -29% | – |
| Cost of Goods Sold | $4 | $3 | $3 | $1 |
| Gross Profit | -$3 | -$3 | -$2 | -$1 |
| % Margin | -573.7% | -575.9% | -1,283.4% | -461.7% |
| R&D Expenses | $0 | $0 | $3 | $1 |
| G&A Expenses | $2 | $2 | $0 | $1 |
| SG&A Expenses | $2 | $2 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$3 | -$1 |
| Operating Expenses | $2 | $2 | $0 | $1 |
| Operating Income | -$5 | -$5 | -$3 | -$2 |
| % Margin | -947.2% | -1,055.6% | -1,406.3% | -738.7% |
| Other Income/Exp. Net | $0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$5 | -$5 | -$3 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$5 | -$3 | -$2 |
| % Margin | -935.2% | -1,027.3% | -1,410.6% | -719.3% |
| EPS | -4.79 | -6.16 | -5.12 | -4 |
| % Growth | 22.2% | -20.3% | -28% | – |
| EPS Diluted | -4.79 | -6.16 | -5.12 | -4.38 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 0 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$5 | -$3 | -$2 |
| % Margin | -934.7% | -1,024.5% | -1,405.4% | -716.7% |